Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,350
  • Shares Outstanding, K 11,340
  • Annual Sales, $ 40 K
  • Annual Income, $ -7,020 K
  • 36-Month Beta 2.37
  • Price/Sales 169.99
  • Price/Cash Flow N/A
  • Price/Book 1.33
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.43 +26.28%
on 10/10/18
1.17 -53.59%
on 09/18/18
-0.58 (-51.73%)
since 09/17/18
3-Month
0.43 +26.28%
on 10/10/18
1.65 -67.09%
on 08/10/18
-1.03 (-65.41%)
since 07/17/18
52-Week
0.43 +26.28%
on 10/10/18
4.80 -88.69%
on 10/20/17
-3.96 (-87.93%)
since 10/17/17

Most Recent Stories

More News
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth

According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a CAGR...

RGBP : 0.0115 (+21.05%)
CRIS : 2.25 (+3.69%)
BPTH : 0.54 (-3.04%)
ATHX : 2.11 (-1.86%)
BLRX : 1.45 (+2.11%)
Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid...

BPTH : 0.54 (-3.04%)
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)
Bio-Path: 2Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.7 million in its second quarter.

BPTH : 0.54 (-3.04%)
Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)
Bio-Path: 1Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.9 million in its first quarter.

BPTH : 0.54 (-3.04%)
Bio-Path Holdings Reports First Quarter 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.54 (-3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade BPTH with:

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

2nd Resistance Point 0.57
1st Resistance Point 0.56
Last Price 0.54
1st Support Level 0.53
2nd Support Level 0.52

See More

52-Week High 4.80
Fibonacci 61.8% 3.13
Fibonacci 50% 2.61
Fibonacci 38.2% 2.10
Last Price 0.54
52-Week Low 0.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar